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threatening complications. Prophylactic acyclovir is routinely
given to patients, which has lessened the prevalence of HSV. When
HSV does not respond to acyclovir, or is found to be resistant to
acyclovir, foscarnet has proven to be a powerful antiviral agent;
however, foscarnet can be very toxic to renal function. This poster
will include general information on this virus and treatments used
to control it, along with nursing considerations for the care of the
pediatric transplantation patient with a reactivation of HSV infec-
tion.
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ASSESSING FOR NUTRITIONAL RISK FACTORS ON A BONE MARROW
TRANSPLANTATION UNIT
Szewczyk, N.A. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
The Assessing for Nutritional Risk Factors clinical project took
place in a bone marrow transplantation (BMT) unit in San Anto-
nio, Texas. The purpose of this project is to develop an assessment
tool for identifying individuals in a BMT inpatient unit who are at
risk for developing complications secondary to inadequate nutri-
tional intake. A secondary goal of this project is to increase nutri-
tional assessment documentation by the nursing staff in this unit.
The Nutritional Risk Assessment Tool (NRAT) preevaluation data
were obtained by interviewing the staff regarding their opinions
about malnutrition in the oncology patient population and the
usefulness of the NRAT on the BMT unit. In addition, the doc-
umentation rate of calorie counts and weights was collected for the
3 months before this project’s implementation.
Results showed a signiﬁcant increase in calorie count documen-
tation and an overall increase in the staff’s awareness about mal-
nutrition in this patient population. The outcomes of this project
include (1) increased awareness of nutritional deﬁcits in the BMT
population in multidisciplinary team members including RNs,
PCAs, and MDs; (2) increased documentation of inadequate di-
etary assessment; and (3) pilot testing of a nutritional assessment
tool.
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SUBJECTIVE SYMPTOMS AND PERFORMANCE STATUS OF SURVIVORS
OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
Choi, S.E., Kim, K.S., Bok, G.N. St. Mary’s Hospital, Catholic HSCT
Center, Seoul, Korea.
Hematopoietic stem cell transplantation(HSCT) is a widely
used treatments for hematologic malignancies and has often
ensured long-term survival of HSCT patients. Concern for
“quality of life” in HSCT patients has increased, and a quality of
life issue becomes recognized as an important outcome of the
treatment. These patients and their families are expecially in-
terested in when they are going to return to “normal” life and
how much time it will take. Therefore, we examined post-
HSCT patients’ subjective symptoms and performance status as
indicators of quality of life.
The ﬁnal samples consisted of 250 patients who had undergone
HSCT at a single center from 1990 to October 2003 and survived
at least 1 year after receiving HSCT. Of the 250 patients, 142 were
male and 108 were female, with a mean age of 33 years. Of the total
patients, 113 patients (59.5%) had been married and 73 patients
(38.4%) wre been single at the time of HSCT.
The patients completed a questionnaire mailed by the research-
ers. Subjective symptom subscales include fatigue, nausea and vom-
iting, pain, dyspnea, insomnia, loss of appetite, constipation, diar-
rhea, and ﬁnancial difﬁculties. The scores of subjective symptoms
range from 0 to 100, with higher scores indicating more severe
symptoms. Performance status was measured in patients over age
16 years using the Karnofsky score and in those under age 16 years
using the Lansky scale.
The median score of subjective symptom after HSCT was 12.2
(range, 0–68.8). The subjective symptom which many of the pa-
tients complained about was ﬁnancial difﬁculties (median, 40),
followed by fatigue (median, 30) and insomnia (median, 17.3). By
3 years, those symptoms had gradually decreased.
The median score of performance status 1–3 years after HSCT
was 80%, but 3 years later it was 90%, indicating that as time went
on, performance status improved. Among the 114 patients who had
been employed before HSCT, 81 (71.1%) continued to work but
30 (26.3%) became unemployed after HSCT. The average time to
return to school and work was 1.27 years (range, 1 to 7 years);
within 2 years after HSCT, 80 patients (72.7%) returned.
In conclusion, those ﬁndings can suggest that until 3 years fol-
lowing HSCT, there should be steady management of physical
symptoms and complications which post-HSCT patients possibly
experience.
Table. Subjective Symptoms and Performance Status after HSCT
1–<2
Year
2–<3
Year
3–4
< Year
4–<5
Year
5 <
Year
Financial
Difficulties 43.00 50.60 38.30 35.70 28.70
Fatigue 38.80 40.60 37.90 27.50 33.40
Subjective
Symptoms 18.90 22.20 15.20 12.00 12.90
Performance
Status 80.10 81.70 90.00 93.20 93.40
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TREATMENT OPTIONS AND NURSING CARE FOR THE PEDIATRIC
APLASTIC ANEMIA PATIENT REQURIRING BONE MARROW OR STEM
CELL TRANSPLANTATION
Baker, J.H., Frey, M.A., Kurtzberg, J. Duke University Medical Cen-
ter, Durham, NC.
Aplastic anemia is a rare, potentially lethal disease that occurs
when the bone marrow stops making enough blood cells. The
condition results in complete bone marrow failure and aplasia.
Common life threatening complications include infection, bleed-
ing, and anemia. The cause of aplastic anemia is unknown but may
be linked to injury to the bone marrow from radiation, chemicals,
viruses, and other causes. The initial diagnosis of aplastic anemia is
often a medical emergency requiring hospitalization and isolation.
The diagnosis is typically made via peripheral blood sampling and
a bone marrow aspirate. Supportive care during the initial period
typically consists of blood component replacement and antimicro-
bial coverage to reduce and treat life-threatening infections. The
gold standard of cure for these patients is bone marrow or stem cell
transplantation. The Duke Pediatric Stem Cell Transplant Pro-
gram has performed 22 transplantations on children with aplastic
anemia. The aims ofthis abstract are as follows:
1. To deﬁne and describe the potential causes of aplastic anemia.
2. To describe the symptoms associated with the onset of the disease, as
well as the sequelae seen with the progression of this disease.
3. To review the latest treatment options, including a detailed analysis of
bone marrow and stem cell transplantation in this patient population.
4. To provide a detailed description of the Duke Pediatric Stem Cell
Transplantation experience regarding this patient population.
5. To provide statistics on the outcomes of transplantation in this group
of children.
6. To identify nursing strategies for the care and support of these patients.
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OPEN ALL NIGHT? VISITING HOURS ON BONE MARROW TRANSPLAN-
TATION UNITS
Rees, L.F. H. Lee Mofﬁtt Cancer Center & Research Institute, Tampa,
FL.
Established visitation policies exist to provide a safe environment,
yet they may be at odds with the psychological needs of patients.
Bone marrow transplantation (BMT) patients experience pro-
longed neutropenia, resulting in protracted lengths of stay. Fami-
lies/caregivers wish to show psychological support by increased
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